TABLE 2.
Reported ALK‐TKI responses in lung cancer with STRN‐ALK fusion
| References | Year | Co‐alterations | ALK‐TKI | Line of treatment | Response |
|---|---|---|---|---|---|
| H. Ren et al. 15 | 2019 | Not mentioned | Crizotinib | 1st‐line | PFS >4 years |
| Y. Yang et al. 16 | 2017 | MYC amplification; TP53 (R181C) | Crizotinib | multiple | CR |
| C. Zhou et al. 17 | 2019 | EGFR (19DEL) |
Crizotinib +gefitinib |
3rd‐line | PR |
| Y. Nakanishi et al. 7 | 2017 | ABCB1 mRNA overexpression | Alectinib | 1st‐line | PD in 3 months |
| C. Su et al. 18 | 2020 | GRM8 (E508K); SETD2 (E1553K) | Alectinib | 1st‐line | PR >19 months |
Abbreviations: ALK, anaplastic lymphoma kinase; CR, complete response; PD, progressive disease; PFS, progression‐free survival; PR, partial response; TKI, tyrosine kinase inhibitor.